MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Papillary renal cell carcinoma (pRCC) is the most frequent non-clear cell subtype of renal cell carcinoma.
• Germline mutations in the MET oncogene are linked to hereditary type I pRCC and some sporadic cases.
• MET inhibition is increasingly recognized as a therapeutic strategy in pRCC.

Purpose of the Study:

• To investigate the role and activation status of the MET oncogene in various subtypes of pRCC.
• To determine the frequency of MET gene alterations and expression levels in sporadic pRCC.
• To explore potential therapeutic targets for pRCC based on MET activation.

Main Methods:

• Analysis of 220 sporadic pRCC samples for gene expression and copy number alterations.
• Utilized whole-genome and comparative genomic microarray analysis.
• Performed MET gene sequencing on type I pRCC samples.

Main Results:

• High MET expression was observed across all pRCC subtypes.
• Copy number gains of MET were identified in 46% of type II and 81% of type I pRCC.
• Somatic MET mutations were found in 21.6% of type I pRCC, with four novel mutations identified.
• LRRK2 kinase was found to be highly correlated with MET expression.

Conclusions:

• MET activation is a significant factor in all pRCC subtypes, positioning it as a potential therapeutic target.
• The findings support the investigation of MET inhibitors for pRCC treatment, guided by MET activation status.
• This study broadens the understanding of MET's role in pRCC, encouraging further clinical research.